BTK inhibition alone is ineffective for the treatment of germinal center B diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma with tonic BCR signaling, which require additional therapeutic targets such as SYK and CXCR4 (5–7). This evidence concerns the gene BCR and diffuse large B-cell lymphoma.